Royal Surrey County Hospital

The trials here

What the 25 trials at this site are about, from their registry records.

Conditions

• Lung cancer6 trials
• Childhood cancers4 trials
• Metastatic breast cancer3 trials
• Bladder cancer2 trials
• Coeliac disease2 trials
• Diabetic eye disease2 trials
• Head and neck cancer2 trials
• Liver and biliary tract cancer2 trials
• Melanoma2 trials
• Prostate cancer2 trials
• Colorectal cancer1 trial
• Osteoarthritis1 trial
• and 1 more

Phase

• Phase 312 trials
• Phase 24 trials
• Phase 2/31 trial

Status

• Completed13 trials
• Active, not recruiting7 trials
• Recruiting2 trials
• Terminated2 trials
• Not yet recruiting1 trial

Lead sponsor

• Hoffmann-La Roche4 trials
• Daiichi Sankyo3 trials
• Institute of Cancer Research, United Kingdom2 trials
• University College, London2 trials
• University of Surrey2 trials
• and 12 more

Running trials

• Recruiting

  Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

  NCT06765109· Phase 3· Nuvalent Inc.· Source

  Contact: Ajay Mehta, MD (principal investigator)

• Recruiting

  A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice

  NCT07284121· Hoffmann-La Roche· Source

• Not yet recruiting

  Supporting Children and Young People to Live Well With Coeliac Disease: A RCT

  NCT06930924· University of Surrey· Source

• Active, not recruiting

  Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

  NCT05352672· Phase 3· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  Stereotactic Body Radiotherapy for the Treatment of OPD

  NCT03256981· Phase 2/3· Institute of Cancer Research, United Kingdom· Source

• Active, not recruiting

  Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer

  NCT02417662· University College, London· Source

• Active, not recruiting

  Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)

  NCT02215265· Phase 3· Lisette Nixon· Source

• Active, not recruiting

  Safety of a Boost (CXB or EBRT) in Combination With Neoadjuvant Chemoradiotherapy for Early Rectal Adenocarcinoma

  NCT02505750· Phase 3· Centre Antoine Lacassagne· Source

• Active, not recruiting

  Total Ankle Replacement Versus Arthrodesis Trial

  NCT02128555· University College, London· Source

• Active, not recruiting

  Prostate Advances in Comparative Evidence

  NCT01584258· Phase 3· Royal Marsden NHS Foundation Trust· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer2 recruiting
• Coeliac disease1 recruiting
• Liver and biliary tract cancer1 recruiting

Closed trials

• Completed

  Supporting Children and Young People to Live Well with Coeliac Disease

  NCT06007898· University of Surrey· Source

• Completed

  Improving Access and Recruitment to Clinical Trials for Lung Cancer Patients

  NCT05888584· Oxford Brookes University· Source

• Completed

  A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy

  NCT05366725· Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany· Source

• Completed

  A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema

  NCT05151731· Phase 2· Hoffmann-La Roche· Source

• Completed

  A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema

  NCT05151744· Phase 2· Hoffmann-La Roche· Source

• Completed

  Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).

  NCT04472429· Phase 3· Incyte Corporation· Source

• Terminated

  A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

  NCT04459715· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice

  NCT03782207· Hoffmann-La Roche· Source

• Completed

  Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

  NCT03734029· Phase 3· Daiichi Sankyo· Source

• Completed

  DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

  NCT03529110· Phase 3· Daiichi Sankyo· Source

• Completed

  Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer

  NCT03511664· Phase 3· Endocyte· Source

• Terminated

  A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

  NCT03248492· Phase 2· Daiichi Sankyo· Source

• Completed

  Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

  NCT03117933· Phase 2· University of Oxford· Source

• Completed

  Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

  NCT01909453· Phase 3· Pfizer· Source

• Completed

  Trial of 1 Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Testis Tumours

  NCT01726374· Phase 3· Institute of Cancer Research, United Kingdom· Source